If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

November 22, 2011

More Renal Cell Carcinoma Clinical Trials

More in Renal Cell Carcinoma Clinical Trials:

Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Sponsors and Collaborators

Beth Israel Deaconess Medical Center

Genentech

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Vanderbilt University

Contact
Daniel Cho, MD
617-632-9250

Biologic Therapy Program
617-632-9250

Principal Investigator
Daniel Cho, MD
Beth Israel Deaconess Medical Center

ClinicalTrials.gov Identifier
NCT00782275

You must be a registered member of RUN to post a comment.

Click here to login | Click here to register

Most Popular
Most Emailed
Most Recent

RENAL & UROLOGY NEWS SITEMAP

Nephrology

Acute Renal Failure
Anemia
Chronic Kidney Disease
Contrast Nephropathy
Cardiovascular Disease
Diabetes
Diabetic Nephropathy
Focal Segmental Glomerulosclerosis
Hemodialysis
Hypertension
Kidney Cancer
Kidney Stones
Lupus Nephritis
Peritoneal Dialysis
Secondary Hyperparathyroidism
Transplantation

Jobs

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

More Renal Cell Carcinoma Clinical Trials

RENAL & UROLOGY NEWS SITEMAP

News

Departments

More

Nephrology

Jobs

Urology

Archives

Other Haymarket Medical Websites

International